Heart transplant patients get new hope against lingering amyloidosis
NCT ID NCT05489523
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 26 times
Summary
This study looks at whether the drug tafamidis can safely stop the progression of ATTR amyloidosis in people who have already had a heart transplant for the disease. About 25 participants will take tafamidis for 12 months. The goal is to see if it stabilizes a key protein in the blood and improves quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN CARDIAC AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai
Beverly Hills, California, 90211, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.